Početna stranicaIPN • EPA
add
Ipsen SA
Preth. zaklj. cijena
107,60 €
Dnevni raspon
108,00 € - 110,20 €
Godišnji raspon
99,70 € - 126,70 €
Tržišna kapitalizacija
9,04 mlr. EUR
Prosječna količina
56,06 tis.
P/E omjer
13,51
Prinos dividende
1,09 %
Glavno tržište vrijednosnica
EPA
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(EUR) | lip 2024.info | Godišnja promjena |
---|---|---|
Prihod | 875,90 mil. | 7,93 % |
Operativni troškovi | 557,05 mil. | 8,31 % |
Neto dohodak | 116,00 mil. | 18,85 % |
Neto profitabilnost | 13,24 | 10,06 % |
Zarada po dionici | — | — |
EBITDA | 240,85 mil. | 0,31 % |
Efektivna porezna stopa | 16,30 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(EUR) | lip 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 485,40 mil. | 17,42 % |
Ukupna imovina | 6,55 mlr. | 7,50 % |
Ukupne obveze | 2,50 mlr. | −6,93 % |
Ukupni kapital | 4,05 mlr. | — |
Dionice u optjecaju | 82,86 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 2,20 | — |
Povrat imovine | 6,13 % | — |
Povrat kapitala | 8,85 % | — |
Tok novca
Neto promjena novca
(EUR) | lip 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | 116,00 mil. | 18,85 % |
Gotovina od poslovanja | 233,00 mil. | 8,52 % |
Gotovina iz ulaganja | −99,55 mil. | 79,81 % |
Gotovina iz financiranja | −159,10 mil. | −51,45 % |
Neto promjena novca | −26,00 mil. | 93,10 % |
Slobodan tok novca | 15,01 mil. | −89,78 % |
Više
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
Glavni izvršni direktor
Osnovano
1929
Web-lokacija
Zaposlenici
5.325